Contact Information CARE/Crawley 7009 Office 513-558-2115 Email hertleek@ucmail.uc.edu Peer Reviewed Publications Abdul-Aziz, Amina; Devine, Raymond D; Lyberger, Justin M; Chang, Hsiaochi; Kovacs, Amy; Lerma, James R; Rogers, Andrew M; Byrd, John C; Hertlein, Erin; Behbehani, Gregory K 2023. Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems. Cells, 12 16, Bhatnagar, Bhavana; Kohlschmidt, Jessica; Orwick, Shelley J; Buelow, Daelynn R; Fobare, Sydney; Oakes, Christopher C; Kolitz, Jonathan E; Uy, Geoff; Stock, Wendy; Powell, Bayard L; Nicolet, Deedra; Hertlein, Erin K; Mrózek, Krzysztof; Blachly, James S; Eisfeld, Ann-Kathrin; Baker, Sharyn D; Byrd, John C 2023. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood advances, 7 16, 4671-4675Eisenmann, Eric D; Stromatt, Jack C; Fobare, Sydney; Huang, Kevin M; Buelow, Daelynn R; Orwick, Shelley; Jeon, Jae Yoon; Weber, Robert H; Larsen, Bill; Mims, Alice S; Hertlein, Erin; Byrd, John C; Baker, Sharyn D 2022. TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion. Cancers, 15 1, Fobare, Sydney; Kohlschmidt, Jessica; Ozer, Hatice Gulcin; Mrózek, Krzysztof; Nicolet, Deedra; Mims, Alice S; Garzon, Ramiro; Blachly, James S; Orwick, Shelley; Carroll, Andrew J; Stone, Richard M; Wang, Eunice S; Kolitz, Jonathan E; Powell, Bayard L; Oakes, Christopher C; Eisfeld, Ann-Kathrin; Hertlein, Erin; Byrd, John C 2022. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood advances, 6 5, 1371-1380Goswami, Swagata; Mani, Rajeswaran; Nunes, Jessica; Chiang, Chi-Ling; Zapolnik, Kevan; Hu, Eileen; Frissora, Frank; Mo, Xiaokui; Walker, Logan A; Yan, Pearlly; Bundschuh, Ralf; Beaver, Larry; Devine, Raymond; Tsai, Yo-Ting; Ventura, Ann; Xie, Zhiliang; Chen, Min; Lapalombella, Rosa; Walker, Alison; Mims, Alice; Larkin, Karilyn; Grieselhuber, Nicole; Bennett, Chad; Phelps, Mitch; Hertlein, Erin; Behbehani, Gregory; Vasu, Sumithira; Byrd, John C; Muthusamy, Natarajan 2022. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood, 139 9, 1340-1358Lucas, Christopher R; Halley, Patrick D; Chowdury, Amjad A; Harrington, Bonnie K; Beaver, Larry; Lapalombella, Rosa; Johnson, Amy J; Hertlein, Erin K; Phelps, Mitch A; Byrd, John C; Castro, Carlos E 2022. DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small (Weinheim an der Bergstrasse, Germany), 18 26, e2108063Chen, Timothy L; Harrington, Bonnie; Truxall, Jean; Wasmuth, Ronni; Prouty, Alexander; Sloan, Shelby; Lehman, Amy M; Sampath, Deepa; Orlemans, Eric; Baiocchi, Robert A; Alinari, Lapo; Byrd, John C; Woyach, Jennifer A; Hertlein, Erin 2021. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of hematology & oncology, 14 1, 36Miller, Cecelia R; Huang, Ying; Ruppert, Amy S; Labanowska, Jadwiga; Jaglowski, Samantha M; Maddocks, Kami J; Rogers, Kerry A; Bhat, Seema; Kittai, Adam S; Grever, Michael; Lapalombella, Rosa; Abruzzo, Lynne V; Heerema, Nyla A; Byrd, John C; Hertlein, Erin K; Woyach, Jennifer A 2021. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 35 11, 3287-3290Elgamal, Ola A; Mehmood, Abeera; Jeon, Jae Yoon; Carmichael, Bridget; Lehman, Amy; Orwick, Shelley J; Truxall, Jean; Goettl, Virginia M; Wasmuth, Ronni; Tran, Minh; Mitchell, Shaneice; Lapalombella, Rosa; Eathiraj, Sudharshan; Schwartz, Brian; Stegmaier, Kimberly; Baker, Sharyn D; Hertlein, Erin; Byrd, John C 2020. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of hematology & oncology, 13 1, 8Jeon, Jae Yoon; Buelow, Daelynn R; Garrison, Dominique A; Niu, Mingshan; Eisenmann, Eric D; Huang, Kevin M; Zavorka Thomas, Megan E; Weber, Robert H; Whatcott, Clifford J; Warner, Steve L; Orwick, Shelley J; Carmichael, Bridget; Stahl, Emily; Brinton, Lindsey T; Lapalombella, Rosa; Blachly, James S; Hertlein, Erin; Byrd, John C; Bhatnagar, Bhavana; Baker, Sharyn D 2020. TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI insight, 5 23, Do, Priscilla; Beckwith, Kyle A; Cheney, Carolyn; Tran, Minh; Beaver, Larry; Griffin, Brittany G; Mo, Xiaokui; Liu, Yang; Lapalombella, Rosa; Hertlein, Erin; Muthusamy, Natarajan; Byrd, John C 2019. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. Journal of immunology (Baltimore, Md. : 1950), 202 9, 2806-2816McWilliams, Emily M; Lucas, Christopher R; Chen, Timothy; Harrington, Bonnie K; Wasmuth, Ronni; Campbell, Amanda; Rogers, Kerry A; Cheney, Carolyn M; Mo, Xiaokui; Andritsos, Leslie A; Awan, Farrukh T; Woyach, Jennifer; Carson, William E; Butchar, Jonathan; Tridandapani, Susheela; Hertlein, Erin; Castro, Carlos E; Muthusamy, Natarajan; Byrd, John C 2019. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood advances, 3 3, 447-460Chen, Timothy L; Tran, Minh; Lakshmanan, Aparna; Harrington, Bonnie K; Gupta, Nikhil; Goettl, Virginia M; Lehman, Amy M; Trudeau, Stephen; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2017. NF-?B p50 (nfkb1) contributes to pathogenesis in the E?-TCL1 mouse model of chronic lymphocytic leukemia. Blood, 130 3, 376-379Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney; Chen, Timothy L; Liu, Chaomei; Lehman, Amy; Blachly, James S; Zhang, Xiaoli; Lucas, David M; Grever, Michael R; Tallman, Martin S; Flinn, Ian W; Rassenti, Laura Z; Kipps, Thomas J; Sampath, Deepa; Coombes, Kevin R; Hertlein, Erin K 2017. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget, 8 16, 25942-25954Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A; Maddocks, Kami J; Labanowska, Jadwiga; Breidenbach, Heather; Lozanski, Gerard; Zhao, Weiqiang; Gordon, Amber L; Jones, Jeffrey A; Flynn, Joseph M; Jaglowski, Samantha M; Andritsos, Leslie A; Blum, Kristie A; T Awan, Farrukh; Rogers, Kerry A; Grever, Michael R; Johnson, Amy J; Abruzzo, Lynne V; Hertlein, Erin K; Blachly, James S; Woyach, Jennifer A; Byrd, John C 2017. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood advances, 1 19, 1584-1588Browning, Rebekah L; Byrd, William H; Gupta, Nikhil; Jones, Jeffrey; Mo, Xiaokui; Hertlein, Erin; Yu, Lianbo; Muthusamy, Natarajan; Byrd, John C 2016. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer immunology research, 4 8, 698-707Chen, Timothy L; Gupta, Nikhil; Lehman, Amy; Ruppert, Amy S; Yu, Lianbo; Oakes, Christopher C; Claus, Rainer; Plass, Christoph; Maddocks, Kami J; Andritsos, Leslie; Jones, Jeffery A; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2016. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget, 7 19, 28684-96Maddocks, Kami; Hertlein, Erin; Chen, Timothy L; Wagner, Amy J; Ling, Yonghua; Flynn, Joseph; Phelps, Mitch; Johnson, Amy J; Byrd, John C; Jones, Jeffrey A 2016. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma, 57 9, 2212-5Balatti, Veronica; Rizzotto, Lara; Miller, Cecelia; Palamarchuk, Alexey; Fadda, Paolo; Pandolfo, Rosantony; Rassenti, Laura Z; Hertlein, Erin; Ruppert, Amy S; Lozanski, Arletta; Lozanski, Gerard; Kipps, Thomas J; Byrd, John C; Croce, Carlo M; Pekarsky, Yuri 2015. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 112 7, 2169-74Guinn, D; Ruppert, A S; Maddocks, K; Jaglowski, S; Gordon, A; Lin, T S; Larson, R; Marcucci, G; Hertlein, E; Woyach, J; Johnson, A J; Byrd, J C 2015. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia, 29 5, 1210-3Kämpjärvi, Kati; Järvinen, Tiina M; Heikkinen, Tuomas; Ruppert, Amy S; Senter, Leigha; Hoag, Kevin W; Dufva, Olli; Kontro, Mika; Rassenti, Laura; Hertlein, Erin; Kipps, Thomas J; Porkka, Kimmo; Byrd, John C; de la Chapelle, Albert; Vahteristo, Pia 2015. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 6 3, 1884-8Liu, Ta-Ming; Ling, Yonghua; Woyach, Jennifer A; Beckwith, Kyle; Yeh, Yuh-Ying; Hertlein, Erin; Zhang, Xiaoli; Lehman, Amy; Awan, Farrukh; Jones, Jeffrey A; Andritsos, Leslie A; Maddocks, Kami; MacMurray, Jessica; Salunke, Santosh B; Chen, Ching-Shih; Phelps, Mitch A; Byrd, John C; Johnson, Amy J 2015. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 125 2, 284-95Tsai, Yo-Ting; Lozanski, Gerard; Lehman, Amy; Sass, Ellen J; Hertlein, Erin; Salunke, Santosh B; Chen, Ching-Shih; Grever, Michael R; Byrd, John C; Lucas, David M 2015. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia research, , Hertlein, Erin 2014. A FOXy target in B-cell survival. Blood, 124 23, 3340-1Gupta, Sneha V; Hertlein, Erin; Lu, Yanhui; Sass, Ellen J; Lapalombella, Rosa; Chen, Timothy L; Davis, Melanie E; Woyach, Jennifer A; Lehman, Amy; Jarjoura, David; Byrd, John C; Lucas, David M 2013. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-?B response in chronic lymphocytic leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 9, 2406-19Hertlein, Erin; Beckwith, Kyle A; Lozanski, Gerard; Chen, Timothy L; Towns, William H; Johnson, Amy J; Lehman, Amy; Ruppert, Amy S; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M; Senter, Leigha; Croce, Carlo M; Symer, David E; de la Chapelle, Albert; Heerema, Nyla A; Byrd, John C 2013. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PloS one, 8 10, e76607Justiniano, Steven E; Elavazhagan, Saranya; Fatehchand, Kavin; Shah, Prexy; Mehta, Payal; Roda, Julie M; Mo, Xiaokui; Cheney, Carolyn; Hertlein, Erin; Eubank, Timothy D; Marsh, Clay; Muthusamy, Natarajan; Butchar, Jonathan P; Byrd, John C; Tridandapani, Susheela 2013. Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. The Journal of biological chemistry, 288 37, 26800-9Mao, Yicheng; Triantafillou, Georgia; Hertlein, Erin; Towns, William; Stefanovski, Matthew; Mo, Xiaokui; Jarjoura, David; Phelps, Mitch; Marcucci, Guido; Lee, Ly James; Goldenberg, David M; Lee, Robert J; Byrd, John C; Muthusamy, Natarajan 2013. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 2, 347-56Alinari, Lapo; Yu, Bo; Christian, Beth A; Yan, Fengting; Shin, Jungook; Lapalombella, Rosa; Hertlein, Erin; Lustberg, Mark E; Quinion, Carl; Zhang, Xiaoli; Lozanski, Gerard; Muthusamy, Natarajan; Prætorius-Ibba, Mette; O'Connor, Owen A; Goldenberg, David M; Byrd, John C; Blum, Kristie A; Baiocchi, Robert A 2011. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood, 117 17, 4530-41Herman, Sarah E M; Gordon, Amber L; Hertlein, Erin; Ramanunni, Asha; Zhang, Xiaoli; Jaglowski, Samantha; Flynn, Joseph; Jones, Jeffrey; Blum, Kristie A; Buggy, Joseph J; Hamdy, Ahmed; Johnson, Amy J; Byrd, John C 2011. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117 23, 6287-96Hertlein, Erin; Byrd, John C 2010. Signalling to drug resistance in CLL. Best practice & research. Clinical haematology, 23 1, 121-31Hertlein, Erin; Byrd, John C 2010. HLA-DR meets ERK. Blood, 115 25, 5126-7Hertlein, Erin; Triantafillou, Georgia; Sass, Ellen J; Hessler, Joshua D; Zhang, Xiaoli; Jarjoura, David; Lucas, David M; Muthusamy, Natarajan; Goldenberg, David M; Lee, Robert J; Byrd, John C 2010. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 116 14, 2554-8Hertlein, Erin; Wagner, Amy J; Jones, Jeffrey; Lin, Thomas S; Maddocks, Kami J; Towns, William H; Goettl, Virginia M; Zhang, Xiaoli; Jarjoura, David; Raymond, Chelsey A; West, Derek A; Croce, Carlo M; Byrd, John C; Johnson, Amy J 2010. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood, 116 1, 45-53Chen, Shih-Shih; Raval, Aparna; Johnson, Amy J; Hertlein, Erin; Liu, Te-Hui; Jin, Victor X; Sherman, Mara H; Liu, Shu-Jun; Dawson, David W; Williams, Katie E; Lanasa, Mark; Liyanarachchi, Sandya; Lin, Thomas S; Marcucci, Guido; Pekarsky, Yuri; Davuluri, Ramana; Croce, Carlo M; Guttridge, Denis C; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106 32, 13433-8Chen, Shih-Shih; Sherman, Mara H; Hertlein, Erin; Johnson, Amy J; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell cycle (Georgetown, Tex.), 8 22, 3663-7Hertlein, Erin; Byrd, John C 2008. CLL and activated NF-kappaB: living partnership. Blood, 111 9, 4427Wang, Huating; Hertlein, Erin; Bakkar, Nadine; Sun, Hao; Acharyya, Swarnali; Wang, Jingxin; Carathers, Micheal; Davuluri, Ramana; Guttridge, Denis C 2007. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Molecular and cellular biology, 27 12, 4374-87Sarkar, Anasuya; Duncan, Michelle; Hart, Judy; Hertlein, Erin; Guttridge, Denis C; Wewers, Mark D 2006. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. Journal of immunology (Baltimore, Md. : 1950), 176 8, 4979-86Hertlein, Erin; Wang, Jingxin; Ladner, Katherine J; Bakkar, Nadine; Guttridge, Denis C 2005. RelA/p65 regulation of IkappaBbeta. Molecular and cellular biology, 25 12, 4956-68
Peer Reviewed Publications Abdul-Aziz, Amina; Devine, Raymond D; Lyberger, Justin M; Chang, Hsiaochi; Kovacs, Amy; Lerma, James R; Rogers, Andrew M; Byrd, John C; Hertlein, Erin; Behbehani, Gregory K 2023. Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems. Cells, 12 16, Bhatnagar, Bhavana; Kohlschmidt, Jessica; Orwick, Shelley J; Buelow, Daelynn R; Fobare, Sydney; Oakes, Christopher C; Kolitz, Jonathan E; Uy, Geoff; Stock, Wendy; Powell, Bayard L; Nicolet, Deedra; Hertlein, Erin K; Mrózek, Krzysztof; Blachly, James S; Eisfeld, Ann-Kathrin; Baker, Sharyn D; Byrd, John C 2023. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood advances, 7 16, 4671-4675Eisenmann, Eric D; Stromatt, Jack C; Fobare, Sydney; Huang, Kevin M; Buelow, Daelynn R; Orwick, Shelley; Jeon, Jae Yoon; Weber, Robert H; Larsen, Bill; Mims, Alice S; Hertlein, Erin; Byrd, John C; Baker, Sharyn D 2022. TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion. Cancers, 15 1, Fobare, Sydney; Kohlschmidt, Jessica; Ozer, Hatice Gulcin; Mrózek, Krzysztof; Nicolet, Deedra; Mims, Alice S; Garzon, Ramiro; Blachly, James S; Orwick, Shelley; Carroll, Andrew J; Stone, Richard M; Wang, Eunice S; Kolitz, Jonathan E; Powell, Bayard L; Oakes, Christopher C; Eisfeld, Ann-Kathrin; Hertlein, Erin; Byrd, John C 2022. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood advances, 6 5, 1371-1380Goswami, Swagata; Mani, Rajeswaran; Nunes, Jessica; Chiang, Chi-Ling; Zapolnik, Kevan; Hu, Eileen; Frissora, Frank; Mo, Xiaokui; Walker, Logan A; Yan, Pearlly; Bundschuh, Ralf; Beaver, Larry; Devine, Raymond; Tsai, Yo-Ting; Ventura, Ann; Xie, Zhiliang; Chen, Min; Lapalombella, Rosa; Walker, Alison; Mims, Alice; Larkin, Karilyn; Grieselhuber, Nicole; Bennett, Chad; Phelps, Mitch; Hertlein, Erin; Behbehani, Gregory; Vasu, Sumithira; Byrd, John C; Muthusamy, Natarajan 2022. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood, 139 9, 1340-1358Lucas, Christopher R; Halley, Patrick D; Chowdury, Amjad A; Harrington, Bonnie K; Beaver, Larry; Lapalombella, Rosa; Johnson, Amy J; Hertlein, Erin K; Phelps, Mitch A; Byrd, John C; Castro, Carlos E 2022. DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small (Weinheim an der Bergstrasse, Germany), 18 26, e2108063Chen, Timothy L; Harrington, Bonnie; Truxall, Jean; Wasmuth, Ronni; Prouty, Alexander; Sloan, Shelby; Lehman, Amy M; Sampath, Deepa; Orlemans, Eric; Baiocchi, Robert A; Alinari, Lapo; Byrd, John C; Woyach, Jennifer A; Hertlein, Erin 2021. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of hematology & oncology, 14 1, 36Miller, Cecelia R; Huang, Ying; Ruppert, Amy S; Labanowska, Jadwiga; Jaglowski, Samantha M; Maddocks, Kami J; Rogers, Kerry A; Bhat, Seema; Kittai, Adam S; Grever, Michael; Lapalombella, Rosa; Abruzzo, Lynne V; Heerema, Nyla A; Byrd, John C; Hertlein, Erin K; Woyach, Jennifer A 2021. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 35 11, 3287-3290Elgamal, Ola A; Mehmood, Abeera; Jeon, Jae Yoon; Carmichael, Bridget; Lehman, Amy; Orwick, Shelley J; Truxall, Jean; Goettl, Virginia M; Wasmuth, Ronni; Tran, Minh; Mitchell, Shaneice; Lapalombella, Rosa; Eathiraj, Sudharshan; Schwartz, Brian; Stegmaier, Kimberly; Baker, Sharyn D; Hertlein, Erin; Byrd, John C 2020. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of hematology & oncology, 13 1, 8Jeon, Jae Yoon; Buelow, Daelynn R; Garrison, Dominique A; Niu, Mingshan; Eisenmann, Eric D; Huang, Kevin M; Zavorka Thomas, Megan E; Weber, Robert H; Whatcott, Clifford J; Warner, Steve L; Orwick, Shelley J; Carmichael, Bridget; Stahl, Emily; Brinton, Lindsey T; Lapalombella, Rosa; Blachly, James S; Hertlein, Erin; Byrd, John C; Bhatnagar, Bhavana; Baker, Sharyn D 2020. TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI insight, 5 23, Do, Priscilla; Beckwith, Kyle A; Cheney, Carolyn; Tran, Minh; Beaver, Larry; Griffin, Brittany G; Mo, Xiaokui; Liu, Yang; Lapalombella, Rosa; Hertlein, Erin; Muthusamy, Natarajan; Byrd, John C 2019. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. Journal of immunology (Baltimore, Md. : 1950), 202 9, 2806-2816McWilliams, Emily M; Lucas, Christopher R; Chen, Timothy; Harrington, Bonnie K; Wasmuth, Ronni; Campbell, Amanda; Rogers, Kerry A; Cheney, Carolyn M; Mo, Xiaokui; Andritsos, Leslie A; Awan, Farrukh T; Woyach, Jennifer; Carson, William E; Butchar, Jonathan; Tridandapani, Susheela; Hertlein, Erin; Castro, Carlos E; Muthusamy, Natarajan; Byrd, John C 2019. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood advances, 3 3, 447-460Chen, Timothy L; Tran, Minh; Lakshmanan, Aparna; Harrington, Bonnie K; Gupta, Nikhil; Goettl, Virginia M; Lehman, Amy M; Trudeau, Stephen; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2017. NF-?B p50 (nfkb1) contributes to pathogenesis in the E?-TCL1 mouse model of chronic lymphocytic leukemia. Blood, 130 3, 376-379Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney; Chen, Timothy L; Liu, Chaomei; Lehman, Amy; Blachly, James S; Zhang, Xiaoli; Lucas, David M; Grever, Michael R; Tallman, Martin S; Flinn, Ian W; Rassenti, Laura Z; Kipps, Thomas J; Sampath, Deepa; Coombes, Kevin R; Hertlein, Erin K 2017. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget, 8 16, 25942-25954Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A; Maddocks, Kami J; Labanowska, Jadwiga; Breidenbach, Heather; Lozanski, Gerard; Zhao, Weiqiang; Gordon, Amber L; Jones, Jeffrey A; Flynn, Joseph M; Jaglowski, Samantha M; Andritsos, Leslie A; Blum, Kristie A; T Awan, Farrukh; Rogers, Kerry A; Grever, Michael R; Johnson, Amy J; Abruzzo, Lynne V; Hertlein, Erin K; Blachly, James S; Woyach, Jennifer A; Byrd, John C 2017. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood advances, 1 19, 1584-1588Browning, Rebekah L; Byrd, William H; Gupta, Nikhil; Jones, Jeffrey; Mo, Xiaokui; Hertlein, Erin; Yu, Lianbo; Muthusamy, Natarajan; Byrd, John C 2016. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer immunology research, 4 8, 698-707Chen, Timothy L; Gupta, Nikhil; Lehman, Amy; Ruppert, Amy S; Yu, Lianbo; Oakes, Christopher C; Claus, Rainer; Plass, Christoph; Maddocks, Kami J; Andritsos, Leslie; Jones, Jeffery A; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2016. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget, 7 19, 28684-96Maddocks, Kami; Hertlein, Erin; Chen, Timothy L; Wagner, Amy J; Ling, Yonghua; Flynn, Joseph; Phelps, Mitch; Johnson, Amy J; Byrd, John C; Jones, Jeffrey A 2016. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma, 57 9, 2212-5Balatti, Veronica; Rizzotto, Lara; Miller, Cecelia; Palamarchuk, Alexey; Fadda, Paolo; Pandolfo, Rosantony; Rassenti, Laura Z; Hertlein, Erin; Ruppert, Amy S; Lozanski, Arletta; Lozanski, Gerard; Kipps, Thomas J; Byrd, John C; Croce, Carlo M; Pekarsky, Yuri 2015. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 112 7, 2169-74Guinn, D; Ruppert, A S; Maddocks, K; Jaglowski, S; Gordon, A; Lin, T S; Larson, R; Marcucci, G; Hertlein, E; Woyach, J; Johnson, A J; Byrd, J C 2015. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia, 29 5, 1210-3Kämpjärvi, Kati; Järvinen, Tiina M; Heikkinen, Tuomas; Ruppert, Amy S; Senter, Leigha; Hoag, Kevin W; Dufva, Olli; Kontro, Mika; Rassenti, Laura; Hertlein, Erin; Kipps, Thomas J; Porkka, Kimmo; Byrd, John C; de la Chapelle, Albert; Vahteristo, Pia 2015. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 6 3, 1884-8Liu, Ta-Ming; Ling, Yonghua; Woyach, Jennifer A; Beckwith, Kyle; Yeh, Yuh-Ying; Hertlein, Erin; Zhang, Xiaoli; Lehman, Amy; Awan, Farrukh; Jones, Jeffrey A; Andritsos, Leslie A; Maddocks, Kami; MacMurray, Jessica; Salunke, Santosh B; Chen, Ching-Shih; Phelps, Mitch A; Byrd, John C; Johnson, Amy J 2015. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 125 2, 284-95Tsai, Yo-Ting; Lozanski, Gerard; Lehman, Amy; Sass, Ellen J; Hertlein, Erin; Salunke, Santosh B; Chen, Ching-Shih; Grever, Michael R; Byrd, John C; Lucas, David M 2015. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia research, , Hertlein, Erin 2014. A FOXy target in B-cell survival. Blood, 124 23, 3340-1Gupta, Sneha V; Hertlein, Erin; Lu, Yanhui; Sass, Ellen J; Lapalombella, Rosa; Chen, Timothy L; Davis, Melanie E; Woyach, Jennifer A; Lehman, Amy; Jarjoura, David; Byrd, John C; Lucas, David M 2013. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-?B response in chronic lymphocytic leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 9, 2406-19Hertlein, Erin; Beckwith, Kyle A; Lozanski, Gerard; Chen, Timothy L; Towns, William H; Johnson, Amy J; Lehman, Amy; Ruppert, Amy S; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M; Senter, Leigha; Croce, Carlo M; Symer, David E; de la Chapelle, Albert; Heerema, Nyla A; Byrd, John C 2013. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PloS one, 8 10, e76607Justiniano, Steven E; Elavazhagan, Saranya; Fatehchand, Kavin; Shah, Prexy; Mehta, Payal; Roda, Julie M; Mo, Xiaokui; Cheney, Carolyn; Hertlein, Erin; Eubank, Timothy D; Marsh, Clay; Muthusamy, Natarajan; Butchar, Jonathan P; Byrd, John C; Tridandapani, Susheela 2013. Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. The Journal of biological chemistry, 288 37, 26800-9Mao, Yicheng; Triantafillou, Georgia; Hertlein, Erin; Towns, William; Stefanovski, Matthew; Mo, Xiaokui; Jarjoura, David; Phelps, Mitch; Marcucci, Guido; Lee, Ly James; Goldenberg, David M; Lee, Robert J; Byrd, John C; Muthusamy, Natarajan 2013. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 2, 347-56Alinari, Lapo; Yu, Bo; Christian, Beth A; Yan, Fengting; Shin, Jungook; Lapalombella, Rosa; Hertlein, Erin; Lustberg, Mark E; Quinion, Carl; Zhang, Xiaoli; Lozanski, Gerard; Muthusamy, Natarajan; Prætorius-Ibba, Mette; O'Connor, Owen A; Goldenberg, David M; Byrd, John C; Blum, Kristie A; Baiocchi, Robert A 2011. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood, 117 17, 4530-41Herman, Sarah E M; Gordon, Amber L; Hertlein, Erin; Ramanunni, Asha; Zhang, Xiaoli; Jaglowski, Samantha; Flynn, Joseph; Jones, Jeffrey; Blum, Kristie A; Buggy, Joseph J; Hamdy, Ahmed; Johnson, Amy J; Byrd, John C 2011. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117 23, 6287-96Hertlein, Erin; Byrd, John C 2010. Signalling to drug resistance in CLL. Best practice & research. Clinical haematology, 23 1, 121-31Hertlein, Erin; Byrd, John C 2010. HLA-DR meets ERK. Blood, 115 25, 5126-7Hertlein, Erin; Triantafillou, Georgia; Sass, Ellen J; Hessler, Joshua D; Zhang, Xiaoli; Jarjoura, David; Lucas, David M; Muthusamy, Natarajan; Goldenberg, David M; Lee, Robert J; Byrd, John C 2010. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 116 14, 2554-8Hertlein, Erin; Wagner, Amy J; Jones, Jeffrey; Lin, Thomas S; Maddocks, Kami J; Towns, William H; Goettl, Virginia M; Zhang, Xiaoli; Jarjoura, David; Raymond, Chelsey A; West, Derek A; Croce, Carlo M; Byrd, John C; Johnson, Amy J 2010. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood, 116 1, 45-53Chen, Shih-Shih; Raval, Aparna; Johnson, Amy J; Hertlein, Erin; Liu, Te-Hui; Jin, Victor X; Sherman, Mara H; Liu, Shu-Jun; Dawson, David W; Williams, Katie E; Lanasa, Mark; Liyanarachchi, Sandya; Lin, Thomas S; Marcucci, Guido; Pekarsky, Yuri; Davuluri, Ramana; Croce, Carlo M; Guttridge, Denis C; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106 32, 13433-8Chen, Shih-Shih; Sherman, Mara H; Hertlein, Erin; Johnson, Amy J; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell cycle (Georgetown, Tex.), 8 22, 3663-7Hertlein, Erin; Byrd, John C 2008. CLL and activated NF-kappaB: living partnership. Blood, 111 9, 4427Wang, Huating; Hertlein, Erin; Bakkar, Nadine; Sun, Hao; Acharyya, Swarnali; Wang, Jingxin; Carathers, Micheal; Davuluri, Ramana; Guttridge, Denis C 2007. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Molecular and cellular biology, 27 12, 4374-87Sarkar, Anasuya; Duncan, Michelle; Hart, Judy; Hertlein, Erin; Guttridge, Denis C; Wewers, Mark D 2006. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. Journal of immunology (Baltimore, Md. : 1950), 176 8, 4979-86Hertlein, Erin; Wang, Jingxin; Ladner, Katherine J; Bakkar, Nadine; Guttridge, Denis C 2005. RelA/p65 regulation of IkappaBbeta. Molecular and cellular biology, 25 12, 4956-68
Abdul-Aziz, Amina; Devine, Raymond D; Lyberger, Justin M; Chang, Hsiaochi; Kovacs, Amy; Lerma, James R; Rogers, Andrew M; Byrd, John C; Hertlein, Erin; Behbehani, Gregory K 2023. Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems. Cells, 12 16, Bhatnagar, Bhavana; Kohlschmidt, Jessica; Orwick, Shelley J; Buelow, Daelynn R; Fobare, Sydney; Oakes, Christopher C; Kolitz, Jonathan E; Uy, Geoff; Stock, Wendy; Powell, Bayard L; Nicolet, Deedra; Hertlein, Erin K; Mrózek, Krzysztof; Blachly, James S; Eisfeld, Ann-Kathrin; Baker, Sharyn D; Byrd, John C 2023. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood advances, 7 16, 4671-4675Eisenmann, Eric D; Stromatt, Jack C; Fobare, Sydney; Huang, Kevin M; Buelow, Daelynn R; Orwick, Shelley; Jeon, Jae Yoon; Weber, Robert H; Larsen, Bill; Mims, Alice S; Hertlein, Erin; Byrd, John C; Baker, Sharyn D 2022. TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion. Cancers, 15 1, Fobare, Sydney; Kohlschmidt, Jessica; Ozer, Hatice Gulcin; Mrózek, Krzysztof; Nicolet, Deedra; Mims, Alice S; Garzon, Ramiro; Blachly, James S; Orwick, Shelley; Carroll, Andrew J; Stone, Richard M; Wang, Eunice S; Kolitz, Jonathan E; Powell, Bayard L; Oakes, Christopher C; Eisfeld, Ann-Kathrin; Hertlein, Erin; Byrd, John C 2022. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood advances, 6 5, 1371-1380Goswami, Swagata; Mani, Rajeswaran; Nunes, Jessica; Chiang, Chi-Ling; Zapolnik, Kevan; Hu, Eileen; Frissora, Frank; Mo, Xiaokui; Walker, Logan A; Yan, Pearlly; Bundschuh, Ralf; Beaver, Larry; Devine, Raymond; Tsai, Yo-Ting; Ventura, Ann; Xie, Zhiliang; Chen, Min; Lapalombella, Rosa; Walker, Alison; Mims, Alice; Larkin, Karilyn; Grieselhuber, Nicole; Bennett, Chad; Phelps, Mitch; Hertlein, Erin; Behbehani, Gregory; Vasu, Sumithira; Byrd, John C; Muthusamy, Natarajan 2022. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood, 139 9, 1340-1358Lucas, Christopher R; Halley, Patrick D; Chowdury, Amjad A; Harrington, Bonnie K; Beaver, Larry; Lapalombella, Rosa; Johnson, Amy J; Hertlein, Erin K; Phelps, Mitch A; Byrd, John C; Castro, Carlos E 2022. DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small (Weinheim an der Bergstrasse, Germany), 18 26, e2108063Chen, Timothy L; Harrington, Bonnie; Truxall, Jean; Wasmuth, Ronni; Prouty, Alexander; Sloan, Shelby; Lehman, Amy M; Sampath, Deepa; Orlemans, Eric; Baiocchi, Robert A; Alinari, Lapo; Byrd, John C; Woyach, Jennifer A; Hertlein, Erin 2021. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of hematology & oncology, 14 1, 36Miller, Cecelia R; Huang, Ying; Ruppert, Amy S; Labanowska, Jadwiga; Jaglowski, Samantha M; Maddocks, Kami J; Rogers, Kerry A; Bhat, Seema; Kittai, Adam S; Grever, Michael; Lapalombella, Rosa; Abruzzo, Lynne V; Heerema, Nyla A; Byrd, John C; Hertlein, Erin K; Woyach, Jennifer A 2021. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 35 11, 3287-3290Elgamal, Ola A; Mehmood, Abeera; Jeon, Jae Yoon; Carmichael, Bridget; Lehman, Amy; Orwick, Shelley J; Truxall, Jean; Goettl, Virginia M; Wasmuth, Ronni; Tran, Minh; Mitchell, Shaneice; Lapalombella, Rosa; Eathiraj, Sudharshan; Schwartz, Brian; Stegmaier, Kimberly; Baker, Sharyn D; Hertlein, Erin; Byrd, John C 2020. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of hematology & oncology, 13 1, 8Jeon, Jae Yoon; Buelow, Daelynn R; Garrison, Dominique A; Niu, Mingshan; Eisenmann, Eric D; Huang, Kevin M; Zavorka Thomas, Megan E; Weber, Robert H; Whatcott, Clifford J; Warner, Steve L; Orwick, Shelley J; Carmichael, Bridget; Stahl, Emily; Brinton, Lindsey T; Lapalombella, Rosa; Blachly, James S; Hertlein, Erin; Byrd, John C; Bhatnagar, Bhavana; Baker, Sharyn D 2020. TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI insight, 5 23, Do, Priscilla; Beckwith, Kyle A; Cheney, Carolyn; Tran, Minh; Beaver, Larry; Griffin, Brittany G; Mo, Xiaokui; Liu, Yang; Lapalombella, Rosa; Hertlein, Erin; Muthusamy, Natarajan; Byrd, John C 2019. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. Journal of immunology (Baltimore, Md. : 1950), 202 9, 2806-2816McWilliams, Emily M; Lucas, Christopher R; Chen, Timothy; Harrington, Bonnie K; Wasmuth, Ronni; Campbell, Amanda; Rogers, Kerry A; Cheney, Carolyn M; Mo, Xiaokui; Andritsos, Leslie A; Awan, Farrukh T; Woyach, Jennifer; Carson, William E; Butchar, Jonathan; Tridandapani, Susheela; Hertlein, Erin; Castro, Carlos E; Muthusamy, Natarajan; Byrd, John C 2019. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood advances, 3 3, 447-460Chen, Timothy L; Tran, Minh; Lakshmanan, Aparna; Harrington, Bonnie K; Gupta, Nikhil; Goettl, Virginia M; Lehman, Amy M; Trudeau, Stephen; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2017. NF-?B p50 (nfkb1) contributes to pathogenesis in the E?-TCL1 mouse model of chronic lymphocytic leukemia. Blood, 130 3, 376-379Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney; Chen, Timothy L; Liu, Chaomei; Lehman, Amy; Blachly, James S; Zhang, Xiaoli; Lucas, David M; Grever, Michael R; Tallman, Martin S; Flinn, Ian W; Rassenti, Laura Z; Kipps, Thomas J; Sampath, Deepa; Coombes, Kevin R; Hertlein, Erin K 2017. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget, 8 16, 25942-25954Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A; Maddocks, Kami J; Labanowska, Jadwiga; Breidenbach, Heather; Lozanski, Gerard; Zhao, Weiqiang; Gordon, Amber L; Jones, Jeffrey A; Flynn, Joseph M; Jaglowski, Samantha M; Andritsos, Leslie A; Blum, Kristie A; T Awan, Farrukh; Rogers, Kerry A; Grever, Michael R; Johnson, Amy J; Abruzzo, Lynne V; Hertlein, Erin K; Blachly, James S; Woyach, Jennifer A; Byrd, John C 2017. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood advances, 1 19, 1584-1588Browning, Rebekah L; Byrd, William H; Gupta, Nikhil; Jones, Jeffrey; Mo, Xiaokui; Hertlein, Erin; Yu, Lianbo; Muthusamy, Natarajan; Byrd, John C 2016. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer immunology research, 4 8, 698-707Chen, Timothy L; Gupta, Nikhil; Lehman, Amy; Ruppert, Amy S; Yu, Lianbo; Oakes, Christopher C; Claus, Rainer; Plass, Christoph; Maddocks, Kami J; Andritsos, Leslie; Jones, Jeffery A; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin 2016. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget, 7 19, 28684-96Maddocks, Kami; Hertlein, Erin; Chen, Timothy L; Wagner, Amy J; Ling, Yonghua; Flynn, Joseph; Phelps, Mitch; Johnson, Amy J; Byrd, John C; Jones, Jeffrey A 2016. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma, 57 9, 2212-5Balatti, Veronica; Rizzotto, Lara; Miller, Cecelia; Palamarchuk, Alexey; Fadda, Paolo; Pandolfo, Rosantony; Rassenti, Laura Z; Hertlein, Erin; Ruppert, Amy S; Lozanski, Arletta; Lozanski, Gerard; Kipps, Thomas J; Byrd, John C; Croce, Carlo M; Pekarsky, Yuri 2015. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 112 7, 2169-74Guinn, D; Ruppert, A S; Maddocks, K; Jaglowski, S; Gordon, A; Lin, T S; Larson, R; Marcucci, G; Hertlein, E; Woyach, J; Johnson, A J; Byrd, J C 2015. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia, 29 5, 1210-3Kämpjärvi, Kati; Järvinen, Tiina M; Heikkinen, Tuomas; Ruppert, Amy S; Senter, Leigha; Hoag, Kevin W; Dufva, Olli; Kontro, Mika; Rassenti, Laura; Hertlein, Erin; Kipps, Thomas J; Porkka, Kimmo; Byrd, John C; de la Chapelle, Albert; Vahteristo, Pia 2015. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 6 3, 1884-8Liu, Ta-Ming; Ling, Yonghua; Woyach, Jennifer A; Beckwith, Kyle; Yeh, Yuh-Ying; Hertlein, Erin; Zhang, Xiaoli; Lehman, Amy; Awan, Farrukh; Jones, Jeffrey A; Andritsos, Leslie A; Maddocks, Kami; MacMurray, Jessica; Salunke, Santosh B; Chen, Ching-Shih; Phelps, Mitch A; Byrd, John C; Johnson, Amy J 2015. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 125 2, 284-95Tsai, Yo-Ting; Lozanski, Gerard; Lehman, Amy; Sass, Ellen J; Hertlein, Erin; Salunke, Santosh B; Chen, Ching-Shih; Grever, Michael R; Byrd, John C; Lucas, David M 2015. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia research, , Hertlein, Erin 2014. A FOXy target in B-cell survival. Blood, 124 23, 3340-1Gupta, Sneha V; Hertlein, Erin; Lu, Yanhui; Sass, Ellen J; Lapalombella, Rosa; Chen, Timothy L; Davis, Melanie E; Woyach, Jennifer A; Lehman, Amy; Jarjoura, David; Byrd, John C; Lucas, David M 2013. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-?B response in chronic lymphocytic leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 9, 2406-19Hertlein, Erin; Beckwith, Kyle A; Lozanski, Gerard; Chen, Timothy L; Towns, William H; Johnson, Amy J; Lehman, Amy; Ruppert, Amy S; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M; Senter, Leigha; Croce, Carlo M; Symer, David E; de la Chapelle, Albert; Heerema, Nyla A; Byrd, John C 2013. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PloS one, 8 10, e76607Justiniano, Steven E; Elavazhagan, Saranya; Fatehchand, Kavin; Shah, Prexy; Mehta, Payal; Roda, Julie M; Mo, Xiaokui; Cheney, Carolyn; Hertlein, Erin; Eubank, Timothy D; Marsh, Clay; Muthusamy, Natarajan; Butchar, Jonathan P; Byrd, John C; Tridandapani, Susheela 2013. Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. The Journal of biological chemistry, 288 37, 26800-9Mao, Yicheng; Triantafillou, Georgia; Hertlein, Erin; Towns, William; Stefanovski, Matthew; Mo, Xiaokui; Jarjoura, David; Phelps, Mitch; Marcucci, Guido; Lee, Ly James; Goldenberg, David M; Lee, Robert J; Byrd, John C; Muthusamy, Natarajan 2013. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 2, 347-56Alinari, Lapo; Yu, Bo; Christian, Beth A; Yan, Fengting; Shin, Jungook; Lapalombella, Rosa; Hertlein, Erin; Lustberg, Mark E; Quinion, Carl; Zhang, Xiaoli; Lozanski, Gerard; Muthusamy, Natarajan; Prætorius-Ibba, Mette; O'Connor, Owen A; Goldenberg, David M; Byrd, John C; Blum, Kristie A; Baiocchi, Robert A 2011. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood, 117 17, 4530-41Herman, Sarah E M; Gordon, Amber L; Hertlein, Erin; Ramanunni, Asha; Zhang, Xiaoli; Jaglowski, Samantha; Flynn, Joseph; Jones, Jeffrey; Blum, Kristie A; Buggy, Joseph J; Hamdy, Ahmed; Johnson, Amy J; Byrd, John C 2011. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117 23, 6287-96Hertlein, Erin; Byrd, John C 2010. Signalling to drug resistance in CLL. Best practice & research. Clinical haematology, 23 1, 121-31Hertlein, Erin; Byrd, John C 2010. HLA-DR meets ERK. Blood, 115 25, 5126-7Hertlein, Erin; Triantafillou, Georgia; Sass, Ellen J; Hessler, Joshua D; Zhang, Xiaoli; Jarjoura, David; Lucas, David M; Muthusamy, Natarajan; Goldenberg, David M; Lee, Robert J; Byrd, John C 2010. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 116 14, 2554-8Hertlein, Erin; Wagner, Amy J; Jones, Jeffrey; Lin, Thomas S; Maddocks, Kami J; Towns, William H; Goettl, Virginia M; Zhang, Xiaoli; Jarjoura, David; Raymond, Chelsey A; West, Derek A; Croce, Carlo M; Byrd, John C; Johnson, Amy J 2010. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood, 116 1, 45-53Chen, Shih-Shih; Raval, Aparna; Johnson, Amy J; Hertlein, Erin; Liu, Te-Hui; Jin, Victor X; Sherman, Mara H; Liu, Shu-Jun; Dawson, David W; Williams, Katie E; Lanasa, Mark; Liyanarachchi, Sandya; Lin, Thomas S; Marcucci, Guido; Pekarsky, Yuri; Davuluri, Ramana; Croce, Carlo M; Guttridge, Denis C; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106 32, 13433-8Chen, Shih-Shih; Sherman, Mara H; Hertlein, Erin; Johnson, Amy J; Teitell, Michael A; Byrd, John C; Plass, Christoph 2009. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell cycle (Georgetown, Tex.), 8 22, 3663-7Hertlein, Erin; Byrd, John C 2008. CLL and activated NF-kappaB: living partnership. Blood, 111 9, 4427Wang, Huating; Hertlein, Erin; Bakkar, Nadine; Sun, Hao; Acharyya, Swarnali; Wang, Jingxin; Carathers, Micheal; Davuluri, Ramana; Guttridge, Denis C 2007. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Molecular and cellular biology, 27 12, 4374-87Sarkar, Anasuya; Duncan, Michelle; Hart, Judy; Hertlein, Erin; Guttridge, Denis C; Wewers, Mark D 2006. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. Journal of immunology (Baltimore, Md. : 1950), 176 8, 4979-86Hertlein, Erin; Wang, Jingxin; Ladner, Katherine J; Bakkar, Nadine; Guttridge, Denis C 2005. RelA/p65 regulation of IkappaBbeta. Molecular and cellular biology, 25 12, 4956-68